IMBRUVICA — Sales to customers (Note 9)
Products & Services · Sales to customers (Note 9)Johnson & Johnson IMBRUVICA — Sales to customers (Note 9) decreased by 5.5% to $1.39B in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 7.8%, from $1.51B to $1.39B. Over 2 years (FY 2021 to FY 2024), IMBRUVICA — Sales to customers (Note 9) shows a downward trend with a -14.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market demand and successful commercial execution, while a decrease may signal increased competition, patent expirations, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total net revenue generated from the sale of a specific oncology therapeutic product to exter...
Peer comparison
Comparable to specific product line revenue disclosures for oncology or specialty pharmaceutical assets at peer companies like AbbVie, Bristol Myers Squibb, or Novartis.
jnj_segment_imbruvica_sales_to_customers_note_9Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.25B | $2.23B | $2.13B | $2.90B | $2.08B | $1.94B | $1.82B | $1.65B | $1.62B | $1.57B | $1.54B | $1.51B | $1.46B | $1.42B | $1.47B | $1.39B |
| QoQ Change | — | -0.8% | -4.4% | +36.0% | -28.4% | -6.6% | -6.0% | -9.3% | -2.2% | -3.1% | -1.7% | -2.3% | -2.9% | -3.0% | +3.7% | -5.5% |
| YoY Change | — | — | — | — | -7.7% | -13.1% | -14.5% | -20.3% | -16.6% | — | -6.8% | -6.9% | — | -9.5% | -4.6% | -7.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's imbruvica — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported imbruvica — sales to customers (note 9) of $1.39B in Q3 2025.
- How has Johnson & Johnson's imbruvica — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's imbruvica — sales to customers (note 9) decreased by 7.8% year-over-year, from $1.51B to $1.39B.
- What is the long-term trend for Johnson & Johnson's imbruvica — sales to customers (note 9)?
- Over 2 years (2021 to 2024), Johnson & Johnson's imbruvica — sales to customers (note 9) has grown at a -14.2% compound annual growth rate (CAGR), from $8.26B to $6.08B.
- What does imbruvica — sales to customers (note 9) mean?
- The total revenue earned from selling a specific oncology drug to customers.